Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents

A. Romano, N. L. Parrinello, M. L. Consoli, L. Marchionni, S. Forte, C. Conticello, A. Pompa, A. Corso, G. Milone, F. Di Raimondo, I. Borrello

Research output: Contribution to journalArticlepeer-review

Abstract

Recent reports identify the ratio between absolute neutrophil count (ANC) and absolute lymphocyte count (ALC), called neutrophil to lymphocyte ratio (NLR), as a predictor of progression-free survival (PFS) and overall survival (OS) in various malignancies. We retrospectively examined the NLR in a cohort of 309 newly diagnosed multiple myeloma (MM) patients treated upfront with novel agents. NLR was calculated using data obtained from the complete blood count (CBC) at diagnosis and subsequently correlated with PFS and OS. The median NLR was 1.9 (range 0.4–15.9). Higher NLR was independent of international staging system (ISS) stage, plasma cell infiltration or cytogenetics. The 5-year PFS and OS estimates were, respectively, 18.2 and 36.4 % for patients with NLR ≥ 2 versus 25.5 and 66.6 % in patients with NLR <2. Among younger patients (age

Original languageEnglish
Pages (from-to)1875-1883
Number of pages9
JournalAnnals of Hematology
Volume94
Issue number11
DOIs
Publication statusPublished - Nov 22 2015

Keywords

  • Granulocyte
  • ISS
  • Lymphocyte
  • Multiple myeloma

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents'. Together they form a unique fingerprint.

Cite this